Internet Explorer does not cooperate with this site. Please see below for options that work with APNA eLearning. *

401-23:  ‘Glorious Glutamate’: Exploring the Neuroscience and Clinical Application of Glutamate and Glutamate Based Therapies

Understand how glutamate functions can negatively impact outcomes in psychiatric disorders. Learn new pharmacologic interventions and applications for daily clinical practice.

Presenter:  Rakesh Jain, MD, MPH

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will not be discussed during this presentation.

Dr. Rakesh Jain, MD, MPH, is on the speakers’ bureau for AbbVie (Allergan), Alkermes, Axsome, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva and Tris Pharmaceutical. Dr. Jain is a Consultant for AbbVie (Allergan), Acadia, Adamas, Alfasigma, Axsome, Biogen, Boehringer Ingleheim, Corium, Cingulate Therapeutics, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva and Transcend Therapeutics. Dr. Jain is on the Advisory board for Adamas, Alkermes, Corium, Eisai, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva and Usona. Dr. Jain is a Researcher for AbbVie (Allergan), Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda.

Session Length:  1 hour 30 minutes

Target Audience:  APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Understand how glutamate can negatively impact outcomes in psychiatric disorders and apply pharmacologic interventions into nursing practice.

Keywords:  Glutamate, Depression, Neurotransmitter, GABA, NMDA, AMPA, Schizophrenia, Anxiety, Pain, Inflammation, Neuroscience

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Access to this course will end: July 31, 2025

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.